Clinical trials sponsored by Beijing Biotech

Phase breakdown

Conditions studied

Recruiting trials led by Beijing Biotech

• Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
  NCT07744256 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
  NCT07523529 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
  NCT07627711 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
  NCT07486089 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
  NCT07627698 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
  NCT07480928 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
  NCT07589517 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
  NCT07641049 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
  NCT07523542 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Beijing Biotech recruiting for?

Beijing Biotech is the lead sponsor of 9 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.